Studies indicate that the median overall survival (OS) for patients with ATRX mutations in the context of IDH-mutant gliomas can extend beyond 24–36 months, significantly longer than the 12–15 months commonly observed in primary (IDH wild-type) glioblastomas [2]. The gene discussed is IDH2; the disease is glioblastoma.